Reply to M. Nayan et al

Signe Benzon Larsen, Christian Dehlendorff, Charlotte Skriver, Susanne Oksbjerg Dalton, Christina Gade Jespersen, Michael Borre, Klaus Brasso, Mette Nørgaard, Christoffer Johansen, Henrik Toft Sørensen, Jesper Hallas, Søren Friis

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

OriginalsprogEngelsk
TidsskriftJournal of Clinical Oncology
Vol/bind36
Udgave nummer6
Sider (fra-til)629-630
Antal sider2
ISSN0732-183X
DOI
StatusUdgivet - 20. feb. 2018

Citer dette

Larsen, S. B., Dehlendorff, C., Skriver, C., Dalton, S. O., Jespersen, C. G., Borre, M., ... Friis, S. (2018). Reply to M. Nayan et al. Journal of Clinical Oncology, 36(6), 629-630. https://doi.org/10.1200/JCO.2017.76.7186
Larsen, Signe Benzon ; Dehlendorff, Christian ; Skriver, Charlotte ; Dalton, Susanne Oksbjerg ; Jespersen, Christina Gade ; Borre, Michael ; Brasso, Klaus ; Nørgaard, Mette ; Johansen, Christoffer ; Sørensen, Henrik Toft ; Hallas, Jesper ; Friis, Søren. / Reply to M. Nayan et al. I: Journal of Clinical Oncology. 2018 ; Bind 36, Nr. 6. s. 629-630.
@article{e30f52e016304ae8baf3d64603c8dd00,
title = "Reply to M. Nayan et al",
keywords = "Denmark, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Prostatic Neoplasms",
author = "Larsen, {Signe Benzon} and Christian Dehlendorff and Charlotte Skriver and Dalton, {Susanne Oksbjerg} and Jespersen, {Christina Gade} and Michael Borre and Klaus Brasso and Mette N{\o}rgaard and Christoffer Johansen and S{\o}rensen, {Henrik Toft} and Jesper Hallas and S{\o}ren Friis",
year = "2018",
month = "2",
day = "20",
doi = "10.1200/JCO.2017.76.7186",
language = "English",
volume = "36",
pages = "629--630",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

Larsen, SB, Dehlendorff, C, Skriver, C, Dalton, SO, Jespersen, CG, Borre, M, Brasso, K, Nørgaard, M, Johansen, C, Sørensen, HT, Hallas, J & Friis, S 2018, 'Reply to M. Nayan et al', Journal of Clinical Oncology, bind 36, nr. 6, s. 629-630. https://doi.org/10.1200/JCO.2017.76.7186

Reply to M. Nayan et al. / Larsen, Signe Benzon; Dehlendorff, Christian; Skriver, Charlotte; Dalton, Susanne Oksbjerg; Jespersen, Christina Gade; Borre, Michael; Brasso, Klaus; Nørgaard, Mette; Johansen, Christoffer; Sørensen, Henrik Toft; Hallas, Jesper; Friis, Søren.

I: Journal of Clinical Oncology, Bind 36, Nr. 6, 20.02.2018, s. 629-630.

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

TY - JOUR

T1 - Reply to M. Nayan et al

AU - Larsen, Signe Benzon

AU - Dehlendorff, Christian

AU - Skriver, Charlotte

AU - Dalton, Susanne Oksbjerg

AU - Jespersen, Christina Gade

AU - Borre, Michael

AU - Brasso, Klaus

AU - Nørgaard, Mette

AU - Johansen, Christoffer

AU - Sørensen, Henrik Toft

AU - Hallas, Jesper

AU - Friis, Søren

PY - 2018/2/20

Y1 - 2018/2/20

KW - Denmark

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Male

KW - Prostatic Neoplasms

U2 - 10.1200/JCO.2017.76.7186

DO - 10.1200/JCO.2017.76.7186

M3 - Comment/debate

C2 - 29261443

AN - SCOPUS:85042133553

VL - 36

SP - 629

EP - 630

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -

Larsen SB, Dehlendorff C, Skriver C, Dalton SO, Jespersen CG, Borre M et al. Reply to M. Nayan et al. Journal of Clinical Oncology. 2018 feb 20;36(6):629-630. https://doi.org/10.1200/JCO.2017.76.7186